Jelle Thole is Founder, and Sr. Advisor Vaccine Development of TuBerculosis Vaccine Initiative (TBVI). He is co-chair of the Steering Committee, and member of the product and clinical development team of TBVI. As part of his role at TBVI, he is seconded as advisor to Biofabri, a human vaccine development and manufacturing company in Porrino, Spain. Jelle Thole is member of Scientific Advisory Board of the Validate Project, UK and member of the Board of the Division of Vaccinology of the Royal Dutch Society for Microbiology, The Netherlands. He has coordinated large integrated EC projects (TBVAC, NEWTBVAC), aiming to develop new vaccines against tuberculosis. Jelle Thole is author of over 70 publications on antigen discovery, host-pathogen interactions, and immunology of human and veterinary mycobacterial pathogens including tuberculosis, paratuberculosis and leprosy.

He is Founder and Member of Scientific Leadership team of TuBerculosis Vaccine Initiative (TBVI). TBVI is a not for profit foundation based in Lelystad, The Netherlands supporting the development new vaccines against human tuberculosis. He is Chair of the Product and Clinical Development team (PDT/CDT) of TBVI, and Chair of Vaccine Program Advisory Group (VPAG) advising DEFRA on a vaccine program against bovine TB in the UK. Jelle Thole is author of over 70 scientific articles on antigen discovery, host-pathogen interactions, and immunology of human and veterinary mycobacterial pathogens including tuberculosis, paratuberculosis and leprosy. He has coordinated large integrated EC FP 6 and 7 projects (TBVAC, NEWTBVAC), aiming to develop new vaccines against tuberculosis.